A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Subjects With Various Degrees of Renal Function
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2017
At a glance
- Drugs Lumicitabine (Primary)
- Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Pharmacokinetics
- Sponsors Janssen Pharmaceutica
- 04 Dec 2017 Planned End Date changed from 22 Dec 2017 to 21 Dec 2017.
- 23 Aug 2017 Status changed from not yet recruiting to recruiting.
- 19 Jun 2017 New trial record